Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar 27;11(4):1026.
doi: 10.3390/biomedicines11041026.

The Association of Leptin with Left Ventricular Hypertrophy in End-Stage Kidney Disease Patients on Dialysis

Susana Coimbra  1   2   3 , Cristina Catarino  1   2 , Maria Sameiro Faria  1   2   4 , José Pedro L Nunes  5 , Susana Rocha  1   2 , Maria João Valente  1   2   6 , Petronila Rocha-Pereira  1   2   7 , Elsa Bronze-da-Rocha  1   2 , Nuno Bettencourt  5 , Ana Beco  4 , Sofia Homem de Melo Marques  4 , José Gerardo Oliveira  8   9 , José Madureira  10 , João Carlos Fernandes  11 , Vasco Miranda  12 , Luís Belo  1   2 , Alice Santos-Silva  1   2
Affiliations

The Association of Leptin with Left Ventricular Hypertrophy in End-Stage Kidney Disease Patients on Dialysis

Susana Coimbra et al. Biomedicines. .

Abstract

Left ventricular hypertrophy (LVH) is a common cardiovascular complication in end-stage kidney disease (ESKD) patients. We aimed at studying the association of LVH with adiponectin and leptin levels, cardiovascular stress/injury biomarkers and nutritional status in these patients. We evaluated the LV mass (LVM) and calculated the LVM index (LVMI) in 196 ESKD patients on dialysis; the levels of hemoglobin, calcium, phosphorus, parathyroid hormone, albumin, adiponectin, leptin, N-terminal pro B-type natriuretic peptide (NT-proBNP) and growth differentiation factor (GDF)-15 were analyzed. ESKD patients with LVH (n = 131) presented higher NT-proBNP and GDF-15, lower hemoglobin and, after adjustment for gender, lower leptin levels compared with non-LVH patients. LVH females also showed lower leptin than the non-LVH female group. In the LVH group, LVMI presented a negative correlation with leptin and a positive correlation with NT-proBNP. Leptin emerged as an independent determinant of LVMI in both groups, and NT-proBNP in the LVH group. Low hemoglobin and leptin and increased calcium, NT-proBNP and dialysis vintage are associated with an increased risk of developing LVH. In ESKD patients on dialysis, LVH is associated with lower leptin values (especially in women), which are negatively correlated with LVMI, and with higher levels of biomarkers of myocardial stress/injury. Leptin and NT-proBNP appear as independent determinants of LVMI; dialysis vintage, hemoglobin, calcium, NT-proBNP and leptin emerged as predicting markers for LVH development. Further studies are needed to better understand the role of leptin in LVH in ESKD patients.

Keywords: GDF-15; NT-proBNP; calcium; hemoglobin; left ventricular mass index; leptin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

Figures

Figure 1
Figure 1
Leptin values for females (F) and males (M) with (LVH) and without left ventricular hypertrophy (non-LVH).
Figure 2
Figure 2
Hemoglobin concentrations for females (F) and males (M) with (LVH) and without left ventricular hypertrophy (non-LVH).
Figure 3
Figure 3
N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations for females (F) and males (M) with (LVH) and without left ventricular hypertrophy (non-LVH).
Figure 4
Figure 4
Schematic view of the predicting biomarkers of left ventricular hypertrophy and potential underlying mechanisms in end-stage kidney disease patients on dialysis, the red arrows indicating potential mechanistic consequences. CVD, cardiovascular disease; Gluc, glucose; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro B-type natriuretic peptide; TG, triglycerides. ↑, higher/increased; ↓ lower/decreased.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Zoccali C., Benedetto F.A., Mallamaci F., Tripepi G., Giacone G., Cataliotti A., Seminara G., Stancanelli B., Malatino L.S. Prognostic Value of Echocardiographic Indicators of Left Ventricular Systolic Function in Asymptomatic Dialysis Patients. J. Am. Soc. Nephrol. 2004;15:1029–1037. doi: 10.1097/01.ASN.0000117977.14912.91. - DOI - PubMed
    1. Shlipak M.G., Fried L.F., Cushman M., Manolio T.A., Peterson D., Stehman-Breen C., Bleyer A., Newman A., Siscovick D., Psaty B. Cardiovascular mortality risk in chronic kidney disease: Comparison of traditional and novel risk factors. JAMA. 2005;293:1737–1745. doi: 10.1001/jama.293.14.1737. - DOI - PubMed
    1. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., Gutierrez O.M., Aguillon-Prada R., Lincoln J., Hare J.M., et al. FGF23 induces left ventricular hypertrophy. J. Clin. Investig. 2011;121:4393–4408. doi: 10.1172/JCI46122. - DOI - PMC - PubMed
    1. Di Lullo L., Gorini A., Russo D., Santoboni A., Ronco C. Left Ventricular Hypertrophy in Chronic Kidney Disease Patients: From Pathophysiology to Treatment. Cardiorenal Med. 2015;5:254–266. doi: 10.1159/000435838. - DOI - PMC - PubMed
    1. Charmetant X., Pecquet M., Poirie P., Agi D., Aupetit J.F., Villar E. Impact of age and renal function on usefulness of NT-proBNP to diagnose heart failure. Clin. Nephrol. 2019;92:65–72. doi: 10.5414/CN109480. - DOI - PubMed